High grade B-cell lymphoma developed in the course of chronic myeloid
leukemia treatment with bosutinib
- Teruhito Takakuwa,
- Ryota Sakai,
- Shiro Koh,
- Hiroshi Okamura,
- Satoru Nanno,
- Yasuhiro Nakashima,
- Takahiko Nakane,
- Hideo Koh,
- Masayuki Hino,
- Hirohisa Nakamae
Ryota Sakai
Osaka City University Graduate School of Medicine School of Medicine
Author ProfileShiro Koh
Osaka City University Graduate School of Medicine School of Medicine
Author ProfileHiroshi Okamura
Osaka City University Graduate School of Medicine School of Medicine
Author ProfileSatoru Nanno
Osaka City University Graduate School of Medicine School of Medicine
Author ProfileYasuhiro Nakashima
Osaka City University Graduate School of Medicine School of Medicine
Author ProfileTakahiko Nakane
Osaka City University Graduate School of Medicine School of Medicine
Author ProfileHideo Koh
Osaka City University Graduate School of Medicine School of Medicine
Author ProfileMasayuki Hino
Osaka City University Graduate School of Medicine School of Medicine
Author ProfileHirohisa Nakamae
Osaka City University Graduate School of Medicine
Author ProfileAbstract
The 75-year-old male patient had been diagnosed with CML 25 years ago.
Over 3 years after starting bosutinib, he was diagnosed with a HGBCL. A
total of six courses of DA-EPOCH-R therapy brought complete remission of
the lymphoma. Eight months after stopping bosutinib, BCR-ABL1 transcript
copies remained undetectable by RT-PCR.26 May 2020Submitted to Clinical Case Reports 27 May 2020Submission Checks Completed
27 May 2020Assigned to Editor
13 Jun 2020Reviewer(s) Assigned
04 Jul 2020Review(s) Completed, Editorial Evaluation Pending
12 Aug 2020Editorial Decision: Revise Minor
29 Nov 20201st Revision Received
11 Dec 2020Submission Checks Completed
11 Dec 2020Assigned to Editor
11 Dec 2020Review(s) Completed, Editorial Evaluation Pending
17 Dec 2020Editorial Decision: Accept
